Development of novel treatment strategy with TM to protect vascular endothelium
| Project/Area Number |
23591421
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
IKEZOE TAKAYUKI 高知大学, 教育研究部医療学系, 講師 (80294833)
|
|---|
| Research Collaborator |
NISHIOKA Chie 高知大学, 医学部, 研究員
YANG Jing 高知大学, 医学部, 外国人特別研究員
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | トロンボモジュリン / 血管内皮細胞 |
|---|
| Research Abstract |
Thrombomodulin (TM) is expressed on the cell surface of endothelial cells and regulates coagulation by inhibiting factor Va and VIIIa via activated protein C. This study found that TM increased levels of anti-apoptotic Mcl-1 in association with activation of extracellular signal-regulated kinase (ERK) and protected endothelial cells from endothelial cell damage caused by inflammatory cytokines and calcineurin inhibitors. Furthermore, we identified that cytoprotective function was localized in epidermal growth factor-like domain and independent from anti-coagulation.
|
Report
(4 results)
Research Products
(25 results)
-
-
-
-
-
-
-
-
[Journal Article] Recombinant human soluble thrombomodu lin safely and effectively rescues ac ute promyelocytic leukemia patients f rom disseminated intravascular coagul ation2012
Author(s)
Ikezoe T, Takeuchi A, Isaka M, Arakaw a Y, Iwabu N, Kin T, Anabuki K, Sakai M, Taniguchi A, Togitani K, Yokoyama A
-
Journal Title
Leuk Res
Volume: 36(11)
Pages: 1398-402
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
